INTRODUCTION
Several point mutations in the b-chain of human Hb, e.g. HbS ( b 6Glu->Val) (Jallow et al., 2009; Williams et al., 2005b) , HbC ( b 6Glu->Lys) (Modiano et al., 2001) and HbE ( b 26Glu->Lys) (Hutagalung et al., 1999) , can confer a survival advantage to Plasmodium (P.) infection (Williams, 2006) . When present in the homozygous form, some of these mutations, e.g. HbS, become pathologic causing hemolytic anemia, leading to accumulation of high levels of cell-free Hb and heme in plasma (Reiter et al., 2002) . Individuals carrying the HbS mutation in the heterozygous form, i.e. the A/S sickle cell trait, also accumulate low (nonpathologic) levels of heme in plasma (Muller-Eberhard et al., 1968) and are protected against malaria (Allison, 1954; Beet, 1947; Jallow et al., 2009; Williams, 2006) .
Once released from Hb, a phenomenon favored in the case of HbS (Hebbel et al., 1988) , free heme becomes cytotoxic Seixas et al., 2009; Gozzelino et al., 2010) . This deleterious effect is countered by the expression of heme oxygenase-1 (HO-1, encoded by the Hmox1 gene) Ferreira et al., 2008; Gozzelino et al., 2010) , a stressresponsive enzyme that catabolizes free heme into biliverdin, iron and carbon monoxide (CO) (Tenhunen et al., 1968) . HO-1 expression is induced by free heme, through a mechanism that involves the ubiquitination-degradation of Kelch-like ECH-associated protein 1 (Keap1) (Kensler et al., 2007) , a cytoplasmic repressor of the transcription factor NF-E2-related factor-2 (Nrf2) (Alam et al., 1999) . Upon nuclear translocation, Nrf2 binds to the stress-responsive elements in the Hmox1 promoter (Ogawa et al., 2001 ), a regulatory mechanism that plays a central role in the control of Hmox1 expression in response to heme (Kensler et al., 2007) .
HO-1 is protective against a wide variety of immune mediated inflammatory diseases Soares and Bach, 2009 ) including experimental cerebral malaria (ECM) (Pamplona et al., 2007) , a lethal neuroinflammatory syndrome that develops in P. berghei ANKA infected C57BL/6 mice and that mimics some of the pathologic features of human cerebral malaria (CM) (Mishra and Newton, 2009 ). This protective effect is mediated by CO, which binds cell-free Hb and inhibits its oxidation, thus preventing heme release from oxidized Hb (Hebbel et al., 1988) and hence the pathogenesis of ECM (Pamplona et al., 2007) . Given that expression of HO-1 (Belcher et al., 2006; Jison et al., 2004) and production of CO (Sears et al., 2001 ) are induced in individuals carrying the HbS mutation we hypothesized that this might explain why individuals carrying the A/S sickle cell trait have a survival advantage against malaria (Allison, 1954; May et al., 2007; Williams et al., 2005b) . We provide evidence demonstrating that this is the case.
RESULTS

Sickle Hb Confers a Survival Advantage against Malaria in Mice
Inoculation of C57BL/6 mice (Hb wt ) with P. berghei ANKA infected red blood cells (RBC) led within 6 to 12 days to the development of clinical signs of ECM ( Figure 1A ). Incidence of ECM was significantly reduced in hemizygous C57BL/6 Hb SAD mice ( Figure 1A ) expressing a b-chain of human Hb carrying the b 6Glu->Val (HbS) mutation as well as two additional mutations, b 23Ala->Ile (Antilles 23I ) and
known to enhance HbS polymerization in humans and mice (Trudel et al., 1991) . Naïve Hb SAD mice present a very mild sickle cell syndrome, which does not lead to anemia (Table S1A available online; Trudel et al., 1994) , similar to the asymptomatic human A/S sickle cell trait that affords protection against malaria (Allison, 1954; Beet, 1947; Jallow et al., 2009) . Hb SAD mice that did not develop ECM, succumbed 20-25 days postinfection from hyperparasitemia-induced anemia (data not shown), a condition unrelated to ECM (Schofield and Grau, 2005) .
When infected with P. berghei ANKA, C57BL/6.Sv/129 Hb A/a mice expressing normal human Hb as well as endogenous mouse Hb (Wu et al., 2006) developed clinical signs of ECM and succumbed 6 to 12 days after infection ( Figure S1A ). Littermate control C57BL/6.Sv/129 Hb a/a mice, expressing only the endogenous mouse Hb developed ECM but with lower incidence, as compared to Hb A/a mice ( Figure S1A ). This suggests that normal human Hb might promote, rather than prevent, the pathogenesis of ECM in C57BL/6.Sv/129 mice. While the reason for this is not clear, it is possible that human Hb alters mouse RBC physiology in a manner that would promote the development of ECM. However, this effect becomes negligible as C57BL/6.Sv/129 mice are backcrossed into the C57BL/6 genetic background ( Figure S1D ), in which ECM incidence is higher than 95% ( Figure 1A ). Given that Hb SAD suppresses the pathogenesis of ECM in C57BL/6 mice and that the deleterious effect of normal human Hb becomes negligible under this genetic background, it is reasonable to infer that the protective effect of Hb SAD is attributable to the mutations in the human b-globin chain rather than to human Hb per se.
Hb SAD mice that did not succumb within 6-12 days postinfection also did not develop the pathologic hallmarks of ECM, including blood brain barrier (BBB) disruption (Figures 1B), perivascular RBC accumulation in brain ( Figure 1B ) and brain edema See also Figure S1 and Figure S2 .
( Figure 1C ). These pathologic features were present in Hb wt (Figures 1B and 1C) and Hb A/a mice, i.e. brain edema ( Figure S1B ).
Given that BBB disruption and brain edema occur in P. berghei ANKA infected C57BL/6 mice via a CD8 + T cell-dependent mechanism (Belnoue et al., 2002; Schofield and Grau, 2005) Figure 1D ). When infected with P. berghei ANKA, Hb wt mice also developed severe lung injury and a mild form of liver injury ( Figure S2 ) with no apparent injury to the kidneys or to the heart (data not shown). The extent of lung and liver injury was reduced in P. berghei ANKA infected Hb SAD versus Hb wt mice ( Figure S2 ).
Sickle Hb Confers Tolerance to Plasmodium Infection in Mice
Protection of Hb SAD mice against ECM was not associated with reduction of pathogen load, as assessed by the percentage of infected RBC, i.e., parasitemia ( Figure 1E Figures 1E and 1F) or Hb A/a mice ( Figures S1C and S1E ). While the protective effect of the human sickle cell trait against malaria has been associated with decreased pathogen load (Allison, 1954; May et al., 2007; Williams et al., 2005b) , there are several instances where this does not appear to be the case (Crompton et al., 2008; Livincstone, 1971; Motulsky et al., 1966) , which is in keeping with the observation that Hb SAD confers protection against ECM without interfering with pathogen load. These observations suggest that mutations in the b-chain of human Hb, such as those in Hb SAD can afford tolerance to Plasmodium infection, a host defense strategy that limits disease severity by preventing tissue damage, without targeting the pathogen. This contrasts to resistance to infection, the well-recognized host defense strategy that limits disease severity by decreasing pathogen load (Raberg et al., 2007; Schneider and Ayres, 2008 
Hmox1
+/-mice, as assessed using a transgenic luciferase-P. berghei ANKA strain ( Figure 4S ). This supports further the notion that induction of HO-1 by sickle Hb confers host tolerance to Plasmodium infection.
Sickle Hb Induces the Expression of HO-1 that Confers Tolerance to Plasmodium Infection Humans and rodents carrying the HbS mutation express high levels of HO-1 in the hematopoietic compartment (Belcher et al., 2006; Jison et al., 2004) . Consistent with this, naïve Hb SAD mice express high levels of Hmox1 mRNA in bone marrow and peripheral blood cells, as compared to naïve Hb wt mice (Figure 2A) . Naïve Hb SAD mice also expressed higher levels of Hmox1 mRNA in the kidneys ( Figure S3A ), which is consistent with the chronic development of kidney injury in these mice, revealed clinically upon aging (Sabaa et al., 2008) . Hb SAD mice expressed similar levels of Hmox1 mRNA in the liver, heart, lung and spleen ( Figure S3A ), as compared to Hb wt mice.
Hb
A/a mice expressed similar levels of Hmox1 mRNA in the bone marrow and peripheral blood versus littermate control Hb a/a mice (Suppl. Figure 3B ), demonstrating that expression of a b S related variant but not a normal b-globin chain is required to induce Hmox1 expression. Given that HO-1 is protective against severe forms of malaria in mice (Pamplona et al., 2007; Seixas et al., 2009) , we asked whether its induction in Hb SAD mice (Figure 2A ) is required to suppress the development of ECM ( Figure 1A) . Figure 2B ), with concomitant development of BBB disruption ( Figure 2C ), brain edema ( Figure 2D ) and sequestration of CD45 high leukocytes (data not shown), CD8 + T cells and activated GrB + CD8 + T cells in the brain ( Figure 2E ) but without noticeable hematological changes (Table S1B ). The protective effect of Hb SAD against lung and liver injury, associated with P. berghei ANKA infection, was lost in Hb
SAD
Hmox1
+/À mice ( Figure S2 ). This was not associated with increased parasite load ( Figure 2F ). Pharmacologic inhibition of HO activity by zinc protoporphyrin IX (ZnPPIX) ( Figures S5A and S5B ), increased ECM incidence in Hb SAD mice versus vehicle-treated controls ( Figure S5C ). This effect was not associated with modulation of parasitemia (Figure S5D) , suggesting that heme catabolism by HO-1 confers tolerance to Plasmodium infection in Hb SAD mice.
Induction of HO-1 by Sickle Hb Inhibits the Production of Chemokines Involved in the Pathogenesis of ECM
Several chemokines can contribute to the pathogenesis of ECM and presumably to that of human CM (Campanella et al., 2008; Schofield and Grau, 2005; Mishra and Newton, 2009 Figure 3A ). The involvement of CXCL10/IP-10 in the pathogenesis of ECM (Campanella et al., 2008) Figure 3B ). This suggests that the inhibitory effect of Hb SAD over the expression of these genes, probably does not involve HO-1. Expression of mRNA encoding the chemokine Ccl19 (MIP-3b) and the chemokine receptor Ccr7 was not modulated by Hb SAD and/or did not involve HO-1 ( Figure 3C ). This was also the case for several other genes previously involved or not in the pathogenesis of ECM ( Figure S6 and Figure S7 ). +/-mice Figure S8 ). Lethality after day 12 postinfection ( Figure 4A ) was most probably due to the development of a ''composite disease'' in which high levels of parasitemia (>20%) synergize with sickle human Hb to cause death, without overt clinical or pathological signs of ECM. These observations reveal that the protective effect of Hb SAD requires the induction of HO-1 expression in hematopoietic cells, consistent with the observed induction of HO-1 expression in blood and bone marrow cells of naïve Hb SAD mice ( Figure 2A ). The protective effect of HO-1 expression in the hematopoietic compartment was not associated with modulation of pathogen load ( Figure 4C and Figure S8C ), confirming that HO-1 affords tolerance to Plasmodium infection. Figure S2 , Figure S3 , Figure S4 , and Figure S5 .
Sickle Hb Confers Tolerance to Plasmodium Infection via HO-1 Expression in Hematopoietic Cells
Sickle Hb Inhibits the Activation/Expansion of CD8 + T Cells Recognizing Antigens Expressed by Plasmodium
The number of splenic CD8 + T cells recognizing specifically a MHC I-restricted epitope derived from glycoprotein B (gB [498] [499] [500] [501] [502] [503] [504] [505] ) of herpes simplex virus-1 expressed by transgenic P. berghei ANKA (Lundie et al., 2008) was reduced in Hb SAD versus Hb wt mice, as assessed five days after infection ( Figure 4A and Figure S9A ). 
Nrf2
+/+ mice ( Figure 5D ), which is consistent with the notion that induction of HO-1 expression by Nrf2 confers tolerance to Plasmodium infection.
Sickle Hb Confers Tolerance to Plasmodium Infection via a Mechanism Involving CO Produced through Heme Catabolism by HO-1 Consistent with similar observations in individuals carrying the HbS mutation in the homozygous (Reiter et al., 2002) or heterozygous (Muller-Eberhard et al., 1968) form, naïve Hb SAD mice had higher concentration of free heme in plasma, as compared to age-matched control naïve Hb wt mice ( Figure 6A ). When pre-exposed in vitro to low levels of free heme cells are protected against a subsequent heme challenge . We asked whether free heme would exert a similar protective effect in vivo. Administration of free heme to Hb wt mice prior to P. berghei ANKA infection suppressed ECM incidence, as compared to vehicle-treated Hb wt mice ( Figure 6B ).
The protective effect of heme was dose-dependent, with higher dosage leading to (1) increased HO-1 expression in whole blood cells ( Figure S1A ) and spleen ( Figure S1B ) and to a lesser extent in the bone marrow ( Figure S11C ) and (2) suppression of ECM ( Figure 11D ). This protective effect was not associated with modulation of parasitemia ( Figure S11D ), suggesting that low concentration of free heme in the plasma of naïve Hb SAD mice (Figure 6a) S12D ). This supports further the notion that the protective effect of Hb SAD against ECM is mediated, to a large extent, via the accumulation of low levels of circulating free heme. Plasma free heme concentration increased significantly following P. berghei ANKA infection in Hb wt mice ( Figure 6A ), an effect we have previously shown to contribute in a critical manner to the pathogenesis of ECM (Ferreira et al., 2008; Pamplona et al., 2007) . Albeit less pronounced this increase was also observed in Hb SAD mice ( Figure 6A ). When challenged with free heme after infection, Hb SAD succumbed to ECM (Figure 6C) , confirmed by the occurrence of brain edema (Figure 6d ). This reveals that free heme has a dual effect in the control of ECM onset, being protective when present at slightly above normal concentration before infection ( Figure 6B ) while highly pathogenic when present at higher levels after infection ( Figure 6C ). Free heme did not interfere with pathogen load (Figures S11E and S11F), revealing that when present at slightly above normal concentration before infection free heme promotes tolerance to malaria, while impairing tolerance to malaria when present at higher concentrations after infection. Heme administration at the same dosage and schedule to naïve Hb wt or Hb SAD mice did not result in lethality (data not shown).
When applied via inhalation to wild type mice, CO suppresses the pathogenesis of ECM via a mechanism that relies on the inhibition of heme release from Hb (Pamplona et al., 2007) . We asked whether the protective effect of Hb SAD against ECM was mediated via this mechanism. Inhaled CO suppressed the incidence of ECM in Hb SAD Hmox1 +/-mice ( Figure 6E ), confirmed by the lack of brain edema ( Figure 6F) . A similar protective effect was observed when CO was applied to P. berghei infected Hb SAD mice treated with the enzymatic HO inhibitor ZnPPIX ( Figures  S5E and S5F ). CO did not modulate parasitemia ( Figure 1G and Figures S11G and S11H). Instead, its protective effect was associated with reduction of plasma free heme concentration, below that of naïve Hb SAD Hmox1 +/-mice ( Figure 6G ). Administration of free heme to infected Hb SAD Hmox1 +/-mice abrogated the protective effect of CO, restoring ECM incidence ( Figure 6H ), confirmed by brain edema ( Figure 6I ). Heme was not toxic when administered at the same dosage and schedule to naïve Hb SAD Hmox1 +/-mice receiving CO, i.e. 0% mortality. These observations demonstrate that sickle Hb suppresses the onset of ECM via the induction of HO-1 and the production of CO, which inhibits the accumulation of free heme thus affording tolerance to Plasmodium infection (Figure 7 ).
DISCUSSION
The protective effect of sickle human Hb against malaria is thought to rely on the reduction of parasite load (Allison, 1954 ; Figure S10 . May et al., 2007; Williams et al., 2005b) , implying that sickle human Hb affords resistance (Raberg et al., 2007; Schneider and Ayres, 2008) to Plasmodium infection. Consistent with this notion, sickle human Hb decreases RBC permissiveness to Plasmodium invasion and growth (Friedman, 1978; Pasvol et al., 1978) while increasing phagocytosis of infected RBC, as assessed ex vivo (Ayi et al., 2004) . Whether these effects account for the protective effect of sickle human Hb in vivo remained to be established. We used a well-established mouse model of malaria allowing for genetic manipulation of the host, to test in vivo the relative contribution of host specific genes to the protective effect of sickle Hb against Plasmodium infection. For technical and ethical reasons these studies can only be performed in rodent models of malaria.
As demonstrated hereby, sickle Hb affords protection against Plasmodium infection in mice ( Figure 1A and Figure 2) , a finding consistent with previous reports using different mouse and Plasmodium strains (Hood et al., 1996; Shear et al., 1993) . This survival advantage occurs irrespectively of parasite load ( Figures 1E and 1F ) and is not associated with modulation of parasite sequestering in different organs ( Figure S4 ), revealing that sickle human Hb confers tolerance (Raberg et al., 2007; Schneider and Ayres, 2008) to Plasmodium infection. This is consistent with our recent observation that heme catabolism by HO-1 also suppresses development of multiple organ dysfunction associated with the pathogenesis of severe sepsis in mice (Larsen et al., 2010) , a lethal outcome of polymicrobial infection that resembles, in some aspects, severe malaria (Clark et al., 2004) . Since the survival advantage conferred by HbS against malaria in human populations can occur without overt decrease of parasite load (Crompton et al., 2008; Livincstone, 1971; Motulsky et al., 1966) , tolerance to Plasmodium infection might also operate in individuals expressing sickle Hb.
We provide evidence for the existence of a specific molecular mechanism via which sickle human Hb confers tolerance to Plasmodium infection. When expressed at nonpathological levels in mice, sickle Hb leads to the accumulation of low concentrations of free heme in plasma ( Figure 6A ). The same is true for individuals carrying the sickle cell trait (Muller-Eberhard et al., 1968) , which affords protection against malaria (Allison, 1954; Beet, 1947; Jallow et al., 2009; Williams, 2006) . Presumably, this is due to the higher rate of heme release from sickle versus normal human Hb (Hebbel et al., 1988) . In the absence of overt inflammation, free heme induces HO-1 expression without causing cytotoxicity Gozzelino et al., 2010) . Presumably, this explains how sickle human Hb induces the expression of HO-1 in human (Jison et al., 2004) and mouse ( Figure 2A prevents the cytotoxic effects of free heme Gozzelino et al., 2010) , hence limiting the pathological outcome of sickle cell anemia in mice (Belcher et al., 2006) . The mechanism via which sickle Hb induces the expression of HO-1 in vivo involves Nrf2 ( Figure 5A ), a transcription factor previously shown to regulate Hmox1 expression (Alam et al., 1999; Kensler et al., 2007) . Induction of HO-1 via Nrf2 affords protection against malaria in Hb SAD mice expressing sickle Hb ( Figure 2B and Figure 5B ). This protective effect occurs irrespectively of parasite load ( Figure 2F and Figure 5D ) or parasite sequestration in different organs ( Figure S4 ), revealing that sickle human Hb affords tolerance to Plasmodium infection via the Nrf2/HO-1 system. The protective effect of HO-1 against sickle cell anemia (Belcher et al., 2006) and against malaria is mediated by the same end-product of heme catabolism, namely CO ( Figures 6E  and 6F ). This gasotransmitter inhibits Hb oxidation and subsequently heme release from Hb (Hebbel et al., 1988) (Figure 6G ), thus preventing free heme from participating in the pathogenesis of ECM ( Figures 6H and 6I ) (Pamplona et al., 2007) (Figure 7) . However, CO might have additional protective effects that contribute to prevent the lethal outcome of Plasmodium infection (Ferreira et al., 2008) .
Other end-products of heme catabolism by HO-1, such as labile iron, might also contribute to the protective effect conferred by sickle Hb against malaria. While cytotoxic per se, labile iron induces the expression of ferritin H chain (FtH) (Berberat et al., 2003; Eisenstein et al., 1991) , which confers cytoprotection against free heme in vitro . We have obtained preliminary evidence suggesting that the cytoprotective effect of FtH is required to support the salutary effects of HO-1 (Seixas et al., 2009 ) against the onset of noncerebral forms of severe malaria in mice (Raffaella Gozzelino, personal communication.
The pathogenesis of ECM relies on a ''multiple hit'' system in which free heme synergizes with other cytotoxic agonists, e.g. pathogenic CD8
+ T cells, to trigger disease onset (Ferreira et al., 2008; Pamplona et al., 2007) . While sickle Hb suppresses both, accumulation of pathogenic free heme ( Figure 6A ) and activation and/or expansion of pathogenic CD8 + T cells ( Figure 4D and e), it appears to do so via different mechanisms. Namely, it inhibits the accumulation of free heme after infection, via the HO-1/CO system ( Figures 6A and G) while restraining the activation and/or expansion of pathogenic CD8 + T cells ( Figure 4D ), via a mechanism that does not seem to involve HO-1 ( Figure 4D and e, Figure S9 ) or Nrf2 ( Figure S10 ). This latter effect is in keeping with the likely immunoregulatory basis of the protective effect of sickle cell trait against severe malaria in human populations (Williams et al., 2005a) . While the immunoregulatory effect of sickle Hb appears to be driven by free heme ( Figure S12 ) its molecular mechanism acts via a signal transduction pathway that remains to be established and that might target antigen presenting cells, e.g. dendritic cells, and/or CD8 + T cells.
Its is possible that chronic hemolysis, associated with oxidation of cell-free Hb and production of circulating free heme, acts as a general protective mechanism against severe forms of malaria in human populations. This would contribute to explain the survival advantage conferred by a variety of RBC mutations against P. falciparum infection. In keeping with this notion, many of these RBC mutations can induce hemolysis (spontaneously or upon oxidative challenge) associated with the accumulation of circulating free heme (Muller-Eberhard et al., 1968) . Some of these also afford protection against CM as illustrated for HbC (May et al., 2007; Modiano et al., 2001) , glucose 6 phosphate dihydrogenase (G6PD) deficiency in males (Guindo et al., 2007) , bor a-thalassemia that confer protection mainly against severe anemia caused by P. falciparum infection (May et al., 2007) as well as other RBC cytoskeleton or membrane protein defects (Williams, 2006) . The notion that chronic hemolysis might be protective per se against severe forms of malaria is strongly supported by the observation that heme administration to naïve mice, is sufficient per se to elicit a protective response ( Figure 6D and Figure S12 ), relying, presumably on the induction of the Nrf2/ HO-1 system. This is however, difficult to prove because the same Nrf2/HO-1 system provides protection against the pathological outcome of some of these RBC mutations, as demonstrated for sickle cell disease (Belcher et al., 2006) .
In conclusion, we suggest that induction of the Nrf2/HO-1 system associated with sickle cell trait and probably with other often clinically silent genetic RBC defects might provide a general protective mechanism against Plasmodium infection in human populations. We propose that modulation of the Nrf2/HO-1 system might be used therapeutically to treat severe forms of malaria and in particular CM.
EXPERIMENTAL PROCEDURES Mice
C57BL/6 Hmox1
+/-mice were provided by Shaw-Fang Yet (Brigham and Women's Hospital, Boston) (Yet et al., 1999) . C57BL/6 Nrf2 -/-mice were provided by the RIKEN BioResource Center (Koyadai, Tsukuba, Ibaraki, Japan) (Itoh et al., 1997) . C57BL/6 Hb SAD mice were provided by Annie Henri (IN-SERM U733 IUH Hô pital Saint-Louis, Paris) (Trudel et al., 1991 
Bone Marrow Chimeras
Bone marrow chimeras were generated in Hmox1
, Hmox1 +/-mice expressing or not the Hb SAD allele (8-10 weeks) as described (Seixas et al., 2009 ).
Parasites, Infection, and Disease assessment Mice were infected with (GFP)-P. berghei ANKA (Pamplona et al., 2007) , GFP-Luciferase P. berghei ANKA (MR4-866) or a (GFP)-P. berghei transgenic parasite expressing different MHC II and MHC I restricted epitopes including the MHC I-restricted epitope derived from glycoprotein B of herpes simplex virus-1 (gB 498-505 ) (Lundie et al., 2008) , provided by William R. Heath (Walter and Eliza Hall, Melbourne, Victoria, Australia). Parasitemias were determined by flow cytometry (Pamplona et al., 2007) . Infected mice were monitored twice daily for clinical symptoms of ECM.
Visualization and Quantification of Luciferase Activity P. berghei ANKA Infected Mice Luciferase activity was visualized by imaging of dissected tissues using an electron multiplying-charge-coupled device (EM-CCD) photon-counting camera (ImagEM, Hamamatsu).
Protoporphyrins
Iron-protoporphyrin IX (FePPIX; heme) and zinc-protoporphyrin IX (ZnPPIX) were dissolved in 0.2 M NaOH, neutralized (pH 7.4) with 0.2 M HCl and administered (i.p.), as described (Pamplona et al., 2007) .
CO Treatment
Mice were placed in a gastight 60 L capacity chamber and exposed continuously between days 4-7 postinfection to CO at a flow rate of $12 L/min (final concentration of 250 parts per million; ppm), as described (Pamplona et al., 2007; Sato et al., 2001) . CO concentration was monitored using a CO analyzer (Interscan Corporation, Chatsworth).
Histology
Brains were harvested, when clinical signs of ECM were noticed in control mice. Tissue was fixed in buffered 4% (vol/vol) paraformaldehyde and histological analysis was performed on perfusion-fixed tissues.
BBB Permeability
Mice were injected intravenously (i.v.) with 0.1 ml of 2% Evans Blue (Sigma) when clinical symptoms of ECM were noticed in control mice (Pamplona et al., 2007) .
Analyzes of Splenic CD8 + T Cell Activation
Intracellular granzyme B staining were performed as described elsewhere (Lundie et al., 2008) . Analyzes of CD8 + T cells recognizing the MHC I-restricted epitope gB 498-505 (SSIEFARL) from glycoprotein B of herpes simplex virus-1, was performed as described elsewhere (Lundie et al., 2008) .
Leukocyte Brain Infiltration
Leukocytes were isolated from the brain of P. berghei ANKA infected mice when clinical symptoms of ECM were detectable in control groups. Brain leukocyte infiltration was quantified by flow cytometry (Pamplona et al., 2007) .
Quantitative Real-Time Reverse Transcription PCR Mice were sacrificed at day ECM onset in Hb wt mice. Hmox1 mRNA was quantified by Quantitative real-time reverse transcription PCR (qRT-PCR) (Roche System) (Pamplona et al., 2007) . TaqManâ Gene Signature Mouse Immune Array (Applied Biosystems) was used to quantify all other mRNAs (7900HT ABI system), according to manufactures recommendations.
Serum Biochemistry
Hematograms were measured by focused flow technology (Hemavet Multispecies Hematology System, HV950FS, Drew Scientific Inc., Centro Diagnó stivo Veteriná rio, Lisboa, Portugal). Plasma Hb was determined by spectroscopy at l=577. Total plasma heme was measured using the 3,3 0 , 5,5 0 tetramethylbenzidine (TMB) peroxidase assay (BD Biosciences), at l=655 nm.
Statistical Analysis
Nonparametric Mann-Whitney U test was used to assess statistical significance between averages in different samples in which n<5. In samples with nR5 the unpaired Student's t-test for unequal variances was used. Normal distributions were confirmed using the Kolmogorov-Smirnov test. Significant differences in survival were evaluated by the generation of Kaplan-Meier plots and by performing log-rank analysis for all experiments in which survival was assessed as an end-point. Statistical analysis for the progeny-expected ratios was performed using Pearson's chi-squared tests. *P<0.05 or **P<0.01 were considered statistically significant.
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